BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Acetylon Pharmaceuticals Announces Preclinical Data of ACY-1215 for the Treatment of Lymphoma Highlighted at 12th International Conference on Malignant Lymphoma (ICML)


6/20/2013 9:07:50 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals Inc., the leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that collaborators from Columbia University Medical Center presented an oral presentation on preclinical data of selective histone deacetylase (HDAC) 6 inhibitor, ACY-1215, in combination with bortezomib (Velcade®, Takeda Millennium Pharmaceuticals) for the treatment of lymphoma at the 12th International Conference on Malignant Lymphoma (ICML), on June 19, 2013, in Lugano, Switzerland. First author Jennifer E. Amengual, M.D., of Columbia University Medical Center presented the study, “Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor, ACY-1215 (ACY), and bortezomib (Bor), demonstrates synergistic antitumor activity in preclinical models of lymphoma.”

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES